TransCode Therapeutics Inc (RNAZ) Quote

Don't get fooled by these institutional tycoons they want your shares

NIH Funding will turn this nuclear!!!

Yo G's The word is out on the Reddit street RNAZ The cure to cancer clearance from FDA

Needs credibility here, Holders got a beat down with celebration news

Government grant award would sure set it's credibility strait

A nightmare here, Shorts are giving it to us up the ass, No guts no glory here

Not for long dude!! 10$ coming…..

RNAZ new 52 lo

It’s coming Phase 1-2 Read carefully https://clinicaltrials.gov/study/NCT06260774?term=Transcode&rank=1

Live the dream news brothers
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
March 28 2024 - 08:30AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.
Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University. Dr. Vlock has successfully supported start-up, emerging, and established companies with diverse product portfolios. He has played key roles in managing pre-IND, phase I, II and III clinical trials, and post–approval studies for more than 40 oncology development programs. While at Pharmacia, Dr. Vlock ran the Celebrex Oncology program involving two pivotal clinical trials and over 3,500 patients. His team was responsible for European approval of Celebrex for the treatment of familial adenomatous polyposis. As CEO of Alopexx, Inc., Dr. Vlock was responsible for the development of drugs in oncology, infectious diseases, Alzheimer’s Disease and muscular dystrophy. His expertise spans important aspects of oncology development, including clinical trial design and strategy, interactions with regulatory agencies, and medical oversight of clinical trials.

“We are delighted to welcome Dr. Vlock in his new role as a senior member of the TransCode team,” said Tom Fitzgerald, CFO and Interim CEO of TransCode. “As a consultant, Dr. Vlock has provided his deep insights into our TTX-MC138 clinical development plan, including our planned Phase 1 clinical trial, and regulatory compliance. Dr. Vlock’s medical and clinical leadership will be invaluable in translating our groundbreaking science to build a robust clinical development program with TTX-MC138, our lead candidate, and our additional pipeline candidates.”

Dr. Vlock obtained his M.D. from Baylor College of Medicine. He completed his residency training in Internal Medicine at Temple University Hospital and a fellowship in Medical Oncology at Yale University School of Medicine. Dr. Vlock initially will serve on a part-time basis through TransCode’s arrangement with BioBridges LLC, a life sciences consulting company.

Walls all busted down dudes, Get ready for blue skies!!!

Bust down that wall dude!!!

What the hell happened at the RNA conference last week dudes!!!!

Come out blazing from bull stable dude!!! Blow the horn off this cancer killer bomb miracle

Short rats need to go to hell, better cover shorties!!!!

No one dumping super tight hands Going to take a bit out of the ask, going to light up the fire

Squeeze the sour lemons

PHASE 1 CLINICAL TRIALS IN THE WORKS

.70 Need to break

Hail Breakthrough in Switzerland RNAZ

At least it bounced back up, about it.

Let's all hold hands and pray for news

RNAZ Presentation Live in Switzerland dudes!!!! RNA Breakthrough baby!!!!

They can't keep it down much longer

Tear down that .63 AMG wall and make the shorts shit in their pants

Good morning Rnaz Live from the swiss alps Take out the news baby!!!!

We hit the low let's all pray for high, let's get high boys and girls

A miracle can happen in Switzerland, The holy grail of cancer research, new hope

RNAZ will be the mother of all short squeeze, Squeeze that lemon dry

Uglier by the day here..

Watch out dudes!!! The dippppppppp is innnnnnnnnn🔥🔥🔥🔥🔥🔥

Tycoon Super Squeeze

Headed south and not much hope for this one it seems.

News hit the wires dude!!!
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11 2024 - 09:00AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics.
Akribion Genomics, a German-based biotechnology start-up, is focused on a CRISPR-derived molecular complex for cancer treatment. TransCode and Akribion are collaborating to develop a technology that combines Akribion’s cell-killing G-dase E, a Class 2 CRISPR nuclease, with TransCode's TTX nucleic acid delivery platform. G-dase E has shown encouraging in vitro results in cells but requires an effective delivery vehicle, such as TTX, to reach intended targets in the body.

Proof-of-concept studies to date suggest that Akribion’s G-dase E ribonucleoprotein complexes could be conjugated to TransCode’s TTX delivery platform, suggesting that the drug candidate could be formulated as intended. These studies also indicate that TTX-G-dase E ribonucleoprotein complexes could be taken up by cancer cells, inducing cancer cell death.

Akribion’s Co-Chief Executive Officer, Lukas Linnig, commented, “We are excited about deepening our relationship with TransCode. Together we have now shown that we can successfully synthesize constructs combining TransCode’s TTX platform and our G-dase E nuclease, demonstrating initial laboratory evidence of efficacy in cancer cells. We look forward to continuing to pursue a combined technology for developing highly targeted drugs to treat cancer.”

Zdravka Medarova, PhD, TransCode Chief Scientific Officer, added, “Establishing proof-of- concept is a critical step in advancing our collaboration. We are fully committed to continuing our joint efforts to developing this technology.”

About TransCode Therapeutics

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

Great call dude!!! Get ready for blue skies up ahead!!!!

Breakthrough coming in switzerland TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
March 06 2024

The presentation will also describe key activities completed in support of TransCode’s planned Phase 1/2 trial for which it plans to file an IND in March 2024.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year’s RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland. The conference is focused on the development of mRNA, RNAi, ASOs, oligonucleotides, vaccines, microRNAs, genome editing, wider nucleic acids and RNA targets. It is expected that delegates from leading companies in these areas will be in attendance.
Details of the Presentation

Stream: Short RNA Based Therapeutics
Title: A First-in-Class Therapy Against Metastatic Cancer: From Pre-Clinical Testing to Early Clinical Trials
Date and Time: March 14th 2:10 p.m. local time
Dr. Medarova’s presentation will describe work completed in support of the TransCode’s ongoing Phase 0 microdose clinical study with its lead therapeutic candidate, TTX-MC138. TTX-MC138 is designed to be delivered to metastatic tumor cells where it is intended to inhibit miR-10b, generally regarded as a master regulator of metastatic disease. In preclinical studies, TTX-MC138 elicited complete responses and life-long disease remission in animal models of adenocarcinoma.

Nonclinical studies to be presented include dosimetry, pharmacokinetics (PK), tissue distribution, and metabolite analysis. In addition, preliminary clinical results including pharmacokinetics and accumulation of the drug candidate in clinical metastases, as well as drug candidate stability, will be discussed. The presentation will also describe key activities completed in support of TransCode’s planned Phase 1/2 trial for which it plans to file an IND in March 2024.

“We are honored to join key stakeholders in the field of RNA to exchange ideas, share compelling data, and ultimately help further this potentially important technology,“ said Medarova. Dr. Medarova continued, “We believe that TTX-MC138 has the potential to help cancer patients as a first-in-class RNA-based treatment for metastatic disease. We are eager to share our progress with the broader scientific community.”

For more information, please visit:

www.transcodetherapeutics.com and https://informaconnect.com/rna-leaders-europe/

About TransCode

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

Still here..

Stick around dude!!! we in switzerland baby!!!

I don’t think I’ll be sticking around waiting for it..

Needs some rocket fuel dude!!!

Like glue this thing is stuck on .70,

The short party is over sweetheart you better like it long from now on , The longer the better 😜

The well is dry dude!! No shares available!! Hold on to your dirty underwears!!

Got some baby powder ready this afternoon

The good news is it’s holding .70. The bad news is it’s stuck at .70

Pharma whales on the look out for news

$o drop your pant$$ fill em bid$$ $weet$$ I got you$$$

Ugh, I’d rather see a basher here.

Bid$$ not getting filled $weet$$$ Drop your pant$$ junkie$$$

One of a kind dude!!! Blue skies coming with cancer breakthrough!!!